Ovarian Cancer Treatment in Shanghai: A Guide for International Patients
Ovarian cancer is the most lethal gynecologic malignancy, accounting for more deaths than cervical and uterine cancer combined. The high mortality rate reflects a fundamental challenge: approximately 75% of patients are diagnosed at an advanced stage (Stage III or IV), when the cancer has spread beyond the ovaries to the peritoneum, lymph nodes, or distant organs. Despite this, ovarian cancer is a disease where surgical expertise, molecular profiling, and access to the latest maintenance therapies can significantly extend survival — and where the choice of treatment center matters enormously.
Shanghai's leading gynecologic oncology programs offer international patients access to high-volume cytoreductive surgery, comprehensive BRCA and molecular testing, PARP inhibitor maintenance therapy, and an active clinical trial landscape. This guide explains the current treatment approach, which specialists and institutions to consider, and how China Medical Concierge Shanghai (CMCS) can coordinate your care.
Understanding Ovarian Cancer: Key Facts
Histological Types: The most common and most aggressive type is high-grade serous ovarian carcinoma (HGSOC), which accounts for approximately 70% of ovarian cancer deaths. Other types include low-grade serous, endometrioid, clear cell, and mucinous carcinomas — each with distinct biology, chemosensitivity, and prognosis. Treatment approaches differ by histological subtype, making accurate pathological diagnosis essential.
Fallopian Tube and Primary Peritoneal Carcinoma: High-grade serous carcinomas arising from the fallopian tube or peritoneum are biologically and clinically similar to ovarian HGSOC and are treated identically. The term "ovarian cancer" in clinical practice often encompasses all three entities.
CA-125: The primary tumor marker for ovarian cancer, used for diagnosis, treatment monitoring, and surveillance. CA-125 is elevated in approximately 80% of advanced ovarian cancers but can be normal in early-stage disease and in some histological subtypes (particularly mucinous and clear cell). HE4 is an additional marker with complementary utility.
Key Molecular Markers in Ovarian Cancer
BRCA1/2 Mutations: The most important biomarkers in ovarian cancer. Germline BRCA1/2 mutations are present in approximately 15–20% of high-grade serous ovarian cancers; somatic (tumor-only) BRCA mutations account for an additional 5–10%. BRCA-mutated ovarian cancers are more sensitive to platinum-based chemotherapy and are eligible for PARP inhibitor maintenance therapy (olaparib, niraparib, rucaparib). All ovarian cancer patients should undergo both germline and somatic BRCA testing.
Homologous Recombination Deficiency (HRD): Beyond BRCA mutations, a broader category of tumors with defects in homologous recombination DNA repair — termed HRD-positive — also benefit from PARP inhibitors. HRD testing (using assays such as Myriad myChoice CDx) identifies this larger population. Approximately 50% of high-grade serous ovarian cancers are HRD-positive.
Microsatellite Instability (MSI-H) / dMMR: Rare in ovarian cancer (approximately 1–2%) but associated with response to pembrolizumab immunotherapy. Testing is recommended as part of comprehensive molecular profiling.
NTRK Fusions, RET Alterations: Rare but actionable alterations identifiable through comprehensive NGS panel testing.
Treatment by Disease Stage
Early-Stage Ovarian Cancer (Stages I–II)
Early-stage ovarian cancer is potentially curable with surgery and adjuvant chemotherapy. The key surgical goals are complete staging (to accurately determine stage and guide adjuvant therapy decisions) and, where possible, fertility-sparing surgery for younger patients who wish to preserve reproductive function.
Surgical staging: Includes total hysterectomy, bilateral salpingo-oophorectomy, omentectomy, peritoneal biopsies, and pelvic/para-aortic lymph node assessment. Minimally invasive (laparoscopic or robotic) staging is appropriate for selected early-stage cases at experienced centers.
Adjuvant chemotherapy: Most Stage I patients with high-grade histology and all Stage II patients receive adjuvant carboplatin + paclitaxel chemotherapy (typically 3–6 cycles).
Advanced Ovarian Cancer (Stages III–IV)
Advanced ovarian cancer requires a combination of surgery and systemic chemotherapy. The sequencing of these modalities — primary debulking surgery (PDS) versus neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS) — is one of the most important treatment decisions and should be made by an experienced gynecologic oncologist and surgeon.
Primary Debulking Surgery (PDS): The goal is complete cytoreduction — removal of all visible tumor (R0 resection). Achieving complete cytoreduction is the single most important prognostic factor in advanced ovarian cancer. This often requires extensive surgery including bowel resection, diaphragm stripping, splenectomy, and other procedures. PDS is appropriate for patients who are fit for major surgery and whose tumors are deemed resectable to no residual disease by an experienced surgeon.
Neoadjuvant Chemotherapy + Interval Debulking Surgery (NACT-IDS): For patients with very extensive disease, poor performance status, or tumors unlikely to be completely resected upfront, 3–4 cycles of neoadjuvant carboplatin + paclitaxel followed by interval debulking surgery is an alternative approach. Response to NACT is assessed by imaging and CA-125 before surgery.
Adjuvant chemotherapy: Following surgery, patients receive carboplatin + paclitaxel for 6 cycles. Bevacizumab (Avastin) may be added to chemotherapy and continued as maintenance in selected patients, particularly those with Stage IV disease or suboptimal cytoreduction.
PARP inhibitor maintenance therapy: After completing first-line platinum-based chemotherapy, maintenance PARP inhibitor therapy has transformed outcomes for ovarian cancer patients:
- Olaparib (Lynparza): Approved for maintenance in BRCA-mutated advanced ovarian cancer after first-line platinum-based chemotherapy. The SOLO-1 trial demonstrated a 70% reduction in risk of progression or death versus placebo.
- Niraparib (Zejula): Approved for maintenance regardless of BRCA status in patients who responded to first-line platinum-based chemotherapy, with greater benefit in HRD-positive tumors.
- Olaparib + bevacizumab: For HRD-positive patients (BRCA-mutated or HRD-positive/BRCA wild-type), the combination of olaparib and bevacizumab maintenance (PAOLA-1 trial) provides additional benefit.
Recurrent Ovarian Cancer
Most advanced ovarian cancer patients will experience recurrence, typically within 18–24 months of completing first-line therapy. Management of recurrent disease depends on the platinum-free interval (PFI) — the time between completing platinum-based chemotherapy and recurrence:
Platinum-sensitive recurrence (PFI ≥6 months): Re-treatment with platinum-based chemotherapy (carboplatin + paclitaxel, carboplatin + gemcitabine, or carboplatin + liposomal doxorubicin) followed by PARP inhibitor maintenance. Secondary cytoreductive surgery may be considered for selected patients with isolated recurrence.
Platinum-resistant recurrence (PFI <6 months): Non-platinum chemotherapy options include liposomal doxorubicin (Doxil), topotecan, gemcitabine, weekly paclitaxel, and etoposide. Bevacizumab may be added. Clinical trial participation is strongly encouraged in this setting.
Mirvetuximab soravtansine (ELAHERE): An antibody-drug conjugate targeting folate receptor alpha (FRα), approved for platinum-resistant ovarian cancer with high FRα expression. FRα testing should be performed on all platinum-resistant patients. Availability in China is expanding through import and clinical trial access.
Immunotherapy: Pembrolizumab for MSI-H/dMMR tumors. Combination immunotherapy strategies are in active clinical development.
Peritoneal Carcinomatosis and HIPEC
Advanced ovarian cancer frequently involves peritoneal spread. Hyperthermic intraperitoneal chemotherapy (HIPEC) — the delivery of heated chemotherapy directly into the abdominal cavity during cytoreductive surgery — has shown survival benefit in selected ovarian cancer patients in the OVHIPEC trial. HIPEC is available at select Shanghai centers with expertise in peritoneal surface oncology. CMCS can identify appropriate candidates and coordinate access to HIPEC programs.
Leading Shanghai Specialists for Ovarian Cancer
Obstetrics & Gynecology Hospital of Fudan University
The Obstetrics & Gynecology Hospital of Fudan University is China's premier institution for gynecologic oncology, with one of the highest volumes of ovarian cancer surgery in the country. CMCS works with Prof. Hua Keqin (华克勤), a nationally recognized gynecologic oncologist with extensive expertise in advanced ovarian cancer surgery, cytoreduction, and systemic therapy. Prof. Hua's team manages complex cases including recurrent and platinum-resistant disease, and has experience with HIPEC and secondary cytoreductive surgery.
Renji Hospital — Shanghai Jiao Tong University
Renji Hospital has an active gynecologic oncology program with strong surgical and medical oncology capabilities for ovarian cancer management.
Ruijin Hospital — Shanghai Jiao Tong University
Ruijin Hospital's gynecology department provides comprehensive ovarian cancer care within a multidisciplinary framework, with access to the full range of systemic therapies including PARP inhibitors.
Genetic Counseling and Hereditary Ovarian Cancer
BRCA1/2 mutations are hereditary in approximately 15–20% of ovarian cancer cases, meaning first-degree relatives (daughters, sisters) have significantly elevated lifetime risk of ovarian and breast cancer. A positive BRCA result has profound implications for the patient's family. CMCS coordinates genetic counseling and cascade testing as part of the consultation process, and can advise on risk-reducing salpingo-oophorectomy for high-risk relatives.
What to Prepare Before Your Shanghai Consultation
- Pathology report with histological type, grade, and any molecular testing results
- BRCA1/2 germline and somatic testing results if available
- HRD testing result (Myriad myChoice or equivalent) if available
- Comprehensive molecular profiling (NGS panel) if available
- Staging imaging: CT chest/abdomen/pelvis, PET-CT if available
- CA-125 and HE4 tumor marker levels (most recent and serial values)
- Prior treatment records: surgery operative reports, chemotherapy regimens, response assessments, PARP inhibitor history
- Surgical records including extent of cytoreduction achieved (residual disease status)
How CMCS Coordinates Ovarian Cancer Care in Shanghai
China Medical Concierge Shanghai (CMCS) is a health management company — not a hospital — that specializes in connecting international patients with Shanghai's leading specialists. For ovarian cancer patients, our coordination includes:
- Case triage to the most appropriate gynecologic oncologist and surgical team based on disease stage, molecular profile, and treatment history
- Medical record translation and clinical summary preparation
- Multidisciplinary tumor board submission and review coordination
- Appointment scheduling across gynecologic oncology, medical oncology, and surgical teams
- On-site interpretation during all consultations and procedures
- BRCA/HRD testing and genetic counseling coordination
- Clinical trial eligibility assessment including HIPEC programs
- PARP inhibitor access coordination
- Post-treatment follow-up and CA-125 surveillance coordination
- Liaison with the patient's home oncologist for continuity of care
Contact CMCS to Begin Your Consultation
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
CMCS – China Medical Concierge Shanghai connects international patients with Shanghai's leading specialists. We are a health management company, not a hospital. All clinical decisions are made by the treating physician. This guide is for informational purposes only and does not constitute medical advice.
0 Kommentare